Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Dose frequency optimization of the dual amylin and calcitonin receptor agonist KBP-088 --long-lasting improvement of food preference and body weight loss.

Larsen AT, Sonne N, Andreassen KV, Karsdal MA, Henriksen K.

J Pharmacol Exp Ther. 2020 Feb 18. pii: jpet.119.263400. doi: 10.1124/jpet.119.263400. [Epub ahead of print]

2.

The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action.

Sonne N, Larsen AT, Andreassen KV, Karsdal MA, Henriksen K.

J Pharmacol Exp Ther. 2020 Apr;373(1):92-102. doi: 10.1124/jpet.119.263723. Epub 2020 Jan 28.

PMID:
31992608
3.

Cost-effectiveness of total knee replacement in addition to non-surgical treatment: a 2-year outcome from a randomised trial in secondary care in Denmark.

Skou ST, Roos E, Laursen M, Arendt-Nielsen L, Rasmussen S, Simonsen O, Ibsen R, Larsen AT, Kjellberg J.

BMJ Open. 2020 Jan 15;10(1):e033495. doi: 10.1136/bmjopen-2019-033495.

4.

The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy.

Larsen AT, Sonne N, Andreassen KV, Gehring K, Karsdal MA, Henriksen K.

J Pharmacol Exp Ther. 2019 Jul;370(1):35-43. doi: 10.1124/jpet.119.257576. Epub 2019 Apr 26.

PMID:
31028106
5.

The P2X7 receptor and pannexin-1 are involved in glucose-induced autocrine regulation in β-cells.

Tozzi M, Larsen AT, Lange SC, Giannuzzo A, Andersen MN, Novak I.

Sci Rep. 2018 Jun 12;8(1):8926. doi: 10.1038/s41598-018-27281-9.

6.

The Socio-economic Impact of Bariatric Surgery.

Larsen AT, Højgaard B, Ibsen R, Kjellberg J.

Obes Surg. 2018 Feb;28(2):338-348. doi: 10.1007/s11695-017-2834-z.

PMID:
28735376
7.

Solution or suspension - Does it matter for lipid based systems? In vivo studies of chase dosing lipid vehicles with aqueous suspensions of a poorly soluble drug.

Larsen AT, Holm R, Müllertz A.

Eur J Pharm Biopharm. 2017 Aug;117:308-314. doi: 10.1016/j.ejpb.2017.04.023. Epub 2017 Apr 29.

PMID:
28465239
8.

Breathing Stimulant Compounds Inhibit TASK-3 Potassium Channel Function Likely by Binding at a Common Site in the Channel Pore.

Chokshi RH, Larsen AT, Bhayana B, Cotten JF.

Mol Pharmacol. 2015 Nov;88(5):926-34. doi: 10.1124/mol.115.100107. Epub 2015 Aug 12.

9.

Thermodynamic insights into 2-thiouridine-enhanced RNA hybridization.

Larsen AT, Fahrenbach AC, Sheng J, Pian J, Szostak JW.

Nucleic Acids Res. 2015 Sep 18;43(16):7675-87. doi: 10.1093/nar/gkv761. Epub 2015 Aug 3.

10.

Uncovering the thermodynamics of monomer binding for RNA replication.

Izgu EC, Fahrenbach AC, Zhang N, Li L, Zhang W, Larsen AT, Blain JC, Szostak JW.

J Am Chem Soc. 2015 May 20;137(19):6373-82. doi: 10.1021/jacs.5b02707. Epub 2015 May 7.

11.

Bioavailability of cinnarizine in dogs: effect of SNEDDS loading level and correlation with cinnarizine solubilization during in vitro lipolysis.

Larsen AT, Åkesson P, Juréus A, Saaby L, Abu-Rmaileh R, Abrahamsson B, Østergaard J, Müllertz A.

Pharm Res. 2013 Dec;30(12):3101-13. doi: 10.1007/s11095-013-1145-x. Epub 2013 Aug 15.

PMID:
23949249
12.

Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation.

Larsen AT, Ohlsson AG, Polentarutti B, Barker RA, Phillips AR, Abu-Rmaileh R, Dickinson PA, Abrahamsson B, Ostergaard J, Müllertz A.

Eur J Pharm Sci. 2013 Jan 23;48(1-2):339-50. doi: 10.1016/j.ejps.2012.11.004. Epub 2012 Nov 21.

PMID:
23178440
13.

SNEDDS Containing Poorly Water Soluble Cinnarizine; Development and in Vitro Characterization of Dispersion, Digestion and Solubilization.

Larsen AT, Ogbonna A, Abu-Rmaileh R, Abrahamsson B, Ostergaard J, Müllertz A.

Pharmaceutics. 2012 Dec 14;4(4):641-65. doi: 10.3390/pharmaceutics4040641.

14.

Predictable stereoselective and chemoselective hydroxylations and epoxidations with P450 3A4.

Larsen AT, May EM, Auclair K.

J Am Chem Soc. 2011 May 25;133(20):7853-8. doi: 10.1021/ja200551y. Epub 2011 Apr 29.

PMID:
21528858
15.

In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems.

Larsen AT, Sassene P, Müllertz A.

Int J Pharm. 2011 Sep 30;417(1-2):245-55. doi: 10.1016/j.ijpharm.2011.03.002. Epub 2011 Mar 15. Review.

PMID:
21392564
16.

Synthesis of 4'-aminopantetheine and derivatives to probe aminoglycoside N-6'-acetyltransferase.

Yan X, Akinnusi TO, Larsen AT, Auclair K.

Org Biomol Chem. 2011 Mar 7;9(5):1538-46. doi: 10.1039/c0ob01018a. Epub 2011 Jan 12.

17.

Pitt-Hopkins syndrome in two patients and further definition of the phenotype.

Peippo MM, Simola KO, Valanne LK, Larsen AT, Kähkönen M, Auranen MP, Ignatius J.

Clin Dysmorphol. 2006 Apr;15(2):47-54.

PMID:
16531728

Supplemental Content

Loading ...
Support Center